Kamil Lisek

1.1k total citations
9 papers, 828 citations indexed

About

Kamil Lisek is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Kamil Lisek has authored 9 papers receiving a total of 828 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 4 papers in Oncology and 3 papers in Cancer Research. Recurrent topics in Kamil Lisek's work include Cancer-related Molecular Pathways (4 papers), Ubiquitin and proteasome pathways (3 papers) and Genomics, phytochemicals, and oxidative stress (2 papers). Kamil Lisek is often cited by papers focused on Cancer-related Molecular Pathways (4 papers), Ubiquitin and proteasome pathways (3 papers) and Genomics, phytochemicals, and oxidative stress (2 papers). Kamil Lisek collaborates with scholars based in Italy, Germany and France. Kamil Lisek's co-authors include Giannino Del Sal, Dawid Walerych, Yari Ciani, Bruna Marini, Hashim Ali, Mauro Giacca, Sándor Pongor, Attila Kertész‐Farkas, Roberto Luzzati and Marina Lušić and has published in prestigious journals such as Nature, Nature Cell Biology and Cancer Research.

In The Last Decade

Kamil Lisek

9 papers receiving 823 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kamil Lisek Italy	9	600	290	191	161	109	9	828
Mathieu Lajoie Canada	14	399 0.7×	158 0.5×	139 0.7×	94 0.6×	45 0.4×	24	712
Louise Boyer-Châtenet France	9	483 0.8×	211 0.7×	96 0.5×	54 0.3×	54 0.5×	12	685
Cynthia L. Innes United States	16	585 1.0×	255 0.9×	192 1.0×	50 0.3×	73 0.7×	30	815
Chiara Vardabasso United States	9	740 1.2×	159 0.5×	120 0.6×	71 0.4×	44 0.4×	12	873
Yanping Wang China	16	328 0.5×	123 0.4×	183 1.0×	79 0.5×	36 0.3×	32	656
Abdeladim Moumen Morocco	11	395 0.7×	166 0.6×	85 0.4×	164 1.0×	21 0.2×	21	580
Shitao Zou China	16	437 0.7×	148 0.5×	185 1.0×	61 0.4×	32 0.3×	38	649
Deborah Silvera United States	11	941 1.6×	227 0.8×	179 0.9×	24 0.1×	71 0.7×	14	1.3k
Matthew W. VanBrocklin United States	15	617 1.0×	275 0.9×	126 0.7×	41 0.3×	81 0.7×	32	1.1k
Takemitsu Nagahata Japan	15	515 0.9×	162 0.6×	86 0.5×	45 0.3×	99 0.9×	24	906

Countries citing papers authored by Kamil Lisek

Since Specialization

Citations

This map shows the geographic impact of Kamil Lisek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kamil Lisek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kamil Lisek more than expected).

Fields of papers citing papers by Kamil Lisek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kamil Lisek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kamil Lisek. The network helps show where Kamil Lisek may publish in the future.

Co-authorship network of co-authors of Kamil Lisek

This figure shows the co-authorship network connecting the top 25 collaborators of Kamil Lisek. A scholar is included among the top collaborators of Kamil Lisek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kamil Lisek. Kamil Lisek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Heynen, Guus J.J.E., Kamil Lisek, Regina Vogel, et al.. (2022). Targeting SHP2 phosphatase in breast cancer overcomes RTK-mediated resistance to PI3K inhibitors. Breast Cancer Research. 24(1). 23–23. 14 indexed citations

2.

Quinn, Hazel M., Regina Vogel, Oliver Popp, et al.. (2021). YAP and β-Catenin Cooperate to Drive Oncogenesis in Basal Breast Cancer. Cancer Research. 81(8). 2116–2127. 51 indexed citations

3.

Lisek, Kamil, et al.. (2018). Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells. Oncotarget. 9(29). 20508–20523. 97 indexed citations

4.

Sorrentino, Giovanni, Rebecca Bertolio, Kamil Lisek, et al.. (2017). Mechanical cues control mutant p53 stability through a mevalonate–RhoA axis. Nature Cell Biology. 20(1). 28–35. 115 indexed citations

5.

Garibaldi, Francesca, Daniela Trisciuoglio, Teresa Colombo, et al.. (2016). Mutant p53 inhibits miRNA biogenesis by interfering with the microprocessor complex. Oncogene. 35(29). 3760–3770. 44 indexed citations

6.

Walerych, Dawid, Kamil Lisek, Roberta Sommaggio, et al.. (2016). Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. Nature Cell Biology. 18(8). 897–909. 185 indexed citations

7.

Lisek, Kamil, Dawid Walerych, & Giannino Del Sal. (2016). Mutant p53–Nrf2 axis regulates the proteasome machinery in cancer. Molecular & Cellular Oncology. 4(1). e1217967–e1217967. 15 indexed citations

8.

Marini, Bruna, Attila Kertész‐Farkas, Hashim Ali, et al.. (2015). Nuclear architecture dictates HIV-1 integration site selection. Nature. 521(7551). 227–231. 235 indexed citations

9.

Walerych, Dawid, Kamil Lisek, & Giannino Del Sal. (2015). Mutant p53: One, No One, and One Hundred Thousand. Frontiers in Oncology. 5. 289–289. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact